Glaucoma, the silent "thief of sight," threatens the vision of 26 million people in China. But now, China's ophthalmology community is fighting back! A revolutionary AI tool called "Xiao Qing" (Little Green) has emerged, partnering with top domestic medical institutions to tackle glaucoma head-on and offer patients a beacon of hope for restoring their sight!

Recently, the "Glaucoma Chronic Disease Management Center," initiated by 12 leading medical institutions including Fudan University Affiliated Eye, Ear, Nose, and Throat Hospital, Sun Yat-sen University Sun Yat-sen Ophthalmic Center, and Beijing Tongren Hospital, was launched in Shanghai. This is not just the formation of a medical alliance, but a technological breakthrough for national eye health. "Xiao Qing," the first AI large language model for glaucoma in China, is the secret weapon in this battle.

Huawei Smart Glasses

You might be amazed by the power of "Xiao Qing." It provides free, authoritative consultations 24/7, interpreting complex medical information and providing accurate, personalized answers in milliseconds – like a tireless, always-available AI ophthalmologist! Even more exciting, "Xiao Qing" isn't just a high-tech gadget; it will partner with home monitoring devices to create a comprehensive "patient-doctor collaborative management" model covering screening, diagnosis, and rehabilitation, allowing patients to receive professional chronic disease management services at home.

The insidious nature of glaucoma is its terrifying aspect. While over 26 million suffer from it, the awareness rate is less than 10%. This means countless individuals are unknowingly on the brink of blindness. Even more heartbreaking, two-thirds of patients are diagnosed in the middle or late stages, with irreversible optic nerve damage. The lack of effective out-of-hospital management in traditional models further exacerbates the situation. But "Xiao Qing" is set to change all that!

Professor Sun Xinghuai, the incoming chairman of the Chinese Medical Doctor Association Ophthalmology Branch, pointed out that intraocular pressure is glaucoma's "only weakness," but it fluctuates daily and seasonally, like a weather forecast. Traditional methods of checking intraocular pressure at the hospital cannot capture its true nature. The innovative home rebound tonometer introduced by the "Glaucoma Chronic Disease Management Center" is like equipping each patient with a "24-hour intraocular pressure monitoring radar." Combined with the intelligent analysis of AI "Xiao Qing," it can create a personalized "intraocular pressure fluctuation curve," giving doctors a clear picture of disease progression for precise intervention!

"Xiao Qing" is not just a theoretical concept. Built on the Deepseek intelligent platform and integrating years of accumulated authoritative knowledge from the ophthalmology community, it boasts strong academic credentials. At the launch event, Professor Zhao Peng, a standing committee member of the Ophthalmology and Visual Science Professional Committee of the Chinese Research Hospital Association, demonstrated "Xiao Qing's" applications. When simulating a patient's inquiry about post-operative care, "Xiao Qing" not only provided the standard answer instantly but also, based on the "virtual medical history," offered personalized advice to "avoid strenuous exercise." This customized intelligent interaction ignited patient enthusiasm, truly achieving seamless "off-site but not off-care" service.

The "14th Five-Year Plan" National Eye Health Plan has elevated the improvement of chronic eye disease management models, the construction of an eye disease chronic disease management system, and the improvement of national eye health to the level of national strategy. The birth of the "Glaucoma Chronic Disease Management Center" and AI "Xiao Qing" is undoubtedly a timely solution, accelerating the realization of this ambitious goal. In the future, every glaucoma patient will have the "golden partnership" of an "AI expert" and "home monitoring devices," enabling home intraocular pressure self-testing and participation in treatment plan development, truly becoming the "first responsible person" for their own health. This will significantly improve treatment compliance and effectiveness, injecting strong technological impetus into the high-quality development of China's eye health cause. The "AI intelligent era" for Chinese ophthalmology has arrived!